A number of other research firms also recently commented on MD. BMO Capital Markets initiated coverage on Mednax in a research report on Monday, October 16th. They set a market perform rating and a $46.00 target price on the stock. Zacks Investment Research upgraded Mednax from a sell rating to a hold rating in a research report on Wednesday, October 11th. Robert W. Baird reiterated a hold rating and set a $47.00 target price on shares of Mednax in a research report on Sunday, September 3rd. BidaskClub downgraded Mednax from a sell rating to a strong sell rating in a research report on Friday, August 4th. Finally, KeyCorp set a $51.00 target price on Mednax and gave the stock a buy rating in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the stock. Mednax currently has a consensus rating of Hold and a consensus target price of $54.50.
Mednax (MD) traded up $2.02 on Friday, reaching $43.37. The company’s stock had a trading volume of 2,080,514 shares, compared to its average volume of 1,302,315. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.59 and a current ratio of 1.37. The stock has a market capitalization of $4,061.82, a P/E ratio of 13.26, a price-to-earnings-growth ratio of 1.41 and a beta of 0.32. Mednax has a one year low of $40.56 and a one year high of $72.13.
Mednax (NYSE:MD) last posted its earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.87. The company had revenue of $868.95 million for the quarter, compared to the consensus estimate of $864.78 million. Mednax had a return on equity of 10.80% and a net margin of 7.76%. Mednax’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.09 earnings per share. equities analysts anticipate that Mednax will post 3.08 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.com-unik.info/2017/11/04/mednax-inc-md-price-target-cut-to-47-00-by-analysts-at-citigroup-inc.html.
In other news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Cesar L. Alvarez sold 10,668 shares of the business’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total value of $454,350.12. Following the completion of the transaction, the director now directly owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. QS Investors LLC raised its holdings in shares of Mednax by 0.3% in the second quarter. QS Investors LLC now owns 3,812 shares of the company’s stock worth $230,000 after acquiring an additional 12 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Mednax by 0.5% in the first quarter. PNC Financial Services Group Inc. now owns 9,099 shares of the company’s stock valued at $632,000 after purchasing an additional 47 shares during the last quarter. Nomura Asset Management Co. Ltd. increased its stake in Mednax by 1.3% in the first quarter. Nomura Asset Management Co. Ltd. now owns 11,300 shares of the company’s stock valued at $784,000 after purchasing an additional 140 shares during the last quarter. Pacer Advisors Inc. increased its stake in Mednax by 8.1% in the second quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock valued at $117,000 after purchasing an additional 145 shares during the last quarter. Finally, State Treasurer State of Michigan increased its stake in Mednax by 0.5% in the second quarter. State Treasurer State of Michigan now owns 38,300 shares of the company’s stock valued at $2,312,000 after purchasing an additional 200 shares during the last quarter. 99.97% of the stock is owned by institutional investors.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
What are top analysts saying about Mednax Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mednax Inc and related companies.